1 unchanged sentence
During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
−Removed: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc., filed with the Secretary of State of the State of Delaware (incorporated by reference to exhibit 3.1 of the Form 8-K filed March 19, 2024)
−Removed: Amendment and Restated Employment Agreement between Moleculin Biotech, Inc.
−Removed: and Walter V.
−Removed: Klemp dated January 4, 2024 (incorporated by reference to exhibit 10.1 of the Form 8-K filed January 5, 2024)
−Removed: Amendment and Restated Employment Agreement between Moleculin Biotech, Inc.
−Removed: and Jonathan P.
−Removed: Foster dated January 4, 2024 (incorporated by reference to exhibit 10.2 of the Form 8-K filed January 5, 2024)
−Removed: Employment Agreement between Moleculin Biotech, Inc.
−Removed: and Donald Picker dated January 4, 2024 (incorporated by reference to exhibit 10.3 of the Form 8-K filed January 5, 2024)
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
16 unchanged sentences
MOLECULIN BIOTECH, INC.
+Added: August 13, 2024
/s/ Walter V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 13, 2024
/s/ Jonathan P.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.